email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2690-5787

LOJ Immunology  & Infectious Disease

Research Article Open Access

Chediak-Higashi Syndrome

Volume 1 - Issue 1

N Khelafi*, MS Ladj, Y Ferhani, R Belbouab, S Sokhal, A Hadji, N Benali Khodja, N Baghdali and R Boukari

  • Author Information Open or Close
    • Pediatrics Department CHU Mustapha, Algiers, Algeria

    *Corresponding author: N Khelafi, Pediatrics Department CHU Mustapha, Algiers, Algeria

Received: June 17, 2019;   Published: June 27, 2019

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Chediak-Higashi syndrome (SCH) is a rare autosomal recessive genetic disorder characterized by oculo-cutaneous albinism, immunodeficiency responsible for recurrent infections, predisposition to bleeding, And late neurological deterioration. The pathognomonic sign is the presence of giant intracytoplasmic granules in most of the cells of the organism but often they are identified in peripheral blood. In 85% of cases, CHS patients develop the accelerated phase characterized by an Hemophagocytic Lymphohistiocytosis syndrome (HLH) responsible for a high mortality rate. The only current effective treatment of haematological and immunological abnormalities remains allogeneic bone marrow transplantation, but without impact on skin manifestations or subsequent neurological deterioration. It is all the more effective as it is performed before the onset of an HLH syndrome.

Abstract| Introduction| Patients and Methods| Results| Discussion| Conclusion| References|